Guggenheim initiated coverage on Zenas Biopharma with a new price target
$ZBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $45.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/20/2025 | $35.00 | Outperform | Wedbush |
| 2/4/2025 | $19.00 | Outperform | Wolfe Research |
| 12/16/2024 | $30.00 | Buy | H.C. Wainwright |
| 11/5/2024 | $34.00 | Buy | Rodman & Renshaw |
| 10/8/2024 | $45.00 | Buy | Guggenheim |
| 10/8/2024 | $40.00 | Overweight | Morgan Stanley |
| 10/8/2024 | $35.00 | Buy | Jefferies |
| 10/8/2024 | $27.00 | Buy | Citigroup |
SCHEDULE 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
S-8 - Zenas BioPharma, Inc. (0001953926) (Filer)
10-K - Zenas BioPharma, Inc. (0001953926) (Filer)
3 - Zenas BioPharma, Inc. (0001953926) (Issuer)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
4 - Zenas BioPharma, Inc. (0001953926) (Issuer)
Wedbush initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $35.00
Wolfe Research initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $19.00
H.C. Wainwright initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $30.00
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s
- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025- -Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025- - Enrollment of Phase 2 Trial in Systemic Lupus Erythematosus (SunStone) expected to be completed in 2025- - Out-licensed greater-China anti-IGF-1R Thyroid Eye Disease programs to Zai Lab - WALTHAM, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmac
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced management's fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 3:00 p.m. ET. A live webcast and archived replay of the Company's presentation can be accessed under "Events and Presentations" in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, Inc. Zenas is a clinical-stage global biopharmaceutica
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s